LuciAle (Alectinib) 150mg Capsules 56-Pack | Lucius Laos Generic Alecensa | GLT

Generic Information: LuciAle (Alectinib) — Laos

LuciAle is Lucius Pharmaceuticals (Lao) Co., Ltd.'s alectinib capsule: 150 mg per capsule, 56 capsules per box, manufactured in Laos for export across Asia, Africa and Latin America. Lucius built its reputation on disciplined, export-oriented oncology generics — a portfolio that tracks the world's most-needed cancer molecules — and LuciAle brings the second-generation ALK inhibitor into that lineup at regional pricing that originator channels cannot approach.

What Is LuciAle (Alectinib) Used For?

LuciAle follows the international alectinib label: ALK-positive metastatic non-small cell lung cancer, as initial systemic therapy and after crizotinib, with the adjuvant post-resection setting referenced as global practice matures. The drug's claim to a place in therapy rests on the brain — ALK-positive disease metastasizes intracranially early and often, and alectinib's central-nervous-system penetration changed what control over that spread looks like. As with every alectinib product, an approved molecular test documenting the ALK rearrangement precedes the first capsule.

How Does LuciAle (Alectinib) Work?

The active molecule inhibits the ALK fusion kinase — including mutation profiles that shrug off crizotinib — and additionally blocks RET kinase as a laboratory target. Blocking ALK shuts down the STAT3 and PI3K/AKT survival signaling that keeps the tumor dividing. The molecule's design lets it accumulate inside the brain by dodging P-gp/BCRP efflux, and its M4 metabolite adds a second, nearly equally potent wave of ALK inhibition. With half-lives near thirty hours, steady twice-daily dosing holds levels flat, and taking doses with food multiplies absorption.

Indications of LuciAle

Concordant with the reference label: first-line treatment of ALK-positive metastatic NSCLC; the same population after crizotinib progression or intolerance; and — as international practice — adjuvant therapy after resection of ALK-positive tumors of 4 cm or more or node-positive. All three gates open only with a validated ALK-positive result in hand.

Dosage and Administration

Standard therapy is 600 mg (four 150 mg capsules) twice daily with food — twenty-eight capsules a week, 112 a fortnight — so a 56-capsule box is a one-week unit and a month runs about five boxes. Severe hepatic impairment (Child-Pugh C) starts at 450 mg twice daily; reductions proceed 450 → 300 mg twice daily with permanent discontinuation below that. Swallow capsules intact; replace a missed dose only when six hours or more remain before the next one; do not re-dose after vomiting.

Side Effects of LuciAle

Day-to-day effects match the class profile: constipation, ankle and eyelid swelling, muscle aches, tiredness, anemia, rash, and a sun-sensitivity that makes sunscreen part of the routine. The events that demand structure are hepatic-enzyme rises, interstitial lung disease, bradycardia, CPK elevation with muscle injury, hemolytic anemia and embryo-fetal toxicity — managed with fortnightly liver panels and CPK early in therapy, pulse and blood pressure at visits, and zero tolerance for unexplained breathlessness or cough without imaging. Contraception counselling belongs in the first conversation.

Storage Instructions

Store below 30°C in the original box, dry and shaded; opened blister material is used within its labeled in-use window. No refrigeration. Out of children's reach; expired capsules return to a pharmacy for disposal.

Why Choose LuciAle from GLT?

LuciAle is the value anchor of GLT's alectinib shelf: a documented Laotian factory, clean packaging, batch verification before dispatch, and pricing that typically sits around 70%–80% below the US list price for the same monthly therapy. For buyers comparing the family — Roche packs from three markets, Everest's Alecnib, TLPH's Alynni, BigBear's Ailedx — LuciAle usually wins on cost-per-month without giving up anything in molecule or strength. Single-family orders and institutional tenders get the same workflow and the same named contact: WhatsApp +86 15234153837, [email protected].

How to Order LuciAle (Alectinib)

Send product and quantity, receive a written quotation with courier and payment options, confirm, and GLT dispatches with full export documentation; CoA and batch photographs are available to institutions before payment. WhatsApp +86 15234153837 and [email protected] are monitored daily, and monthly standing orders can be scheduled so therapy never gaps.

FAQ

Who manufactures LuciAle? Lucius Pharmaceuticals (Lao) Co., Ltd., a Laos-based export generics manufacturer; GLT verifies batch documentation on every lot.

What does a month cost versus the originator? At the standard schedule a month runs about five 56-capsule boxes; GLT quotes LuciAle typically around 70%–80% below US list pricing for the same therapy — ask for today's figure.

Same capsule as Alecensa? Same molecule and strength; the factory, packaging and price are what differ.

Can I switch from crizotinib to LuciAle? That is one of its registered-use settings — plan the switch with your oncologist.

Do you sell single boxes? Yes — families can start with one box; institutions get carton-level terms.